Document is current
Any future updates will be listed below
-
Authors
Fenwick, Craig https://orcid.org/0000-0002-9435-0110
Turelli, Priscilla https://orcid.org/0000-0002-7302-9977
Ni, Dongchun
Perez, Laurent https://orcid.org/0000-0002-8860-7928
Lau, Kelvin https://orcid.org/0000-0002-9040-7597
Herate, Cécile
Marlin, Romain
Lana, Erica
Pellaton, Céline
Raclot, Charlène https://orcid.org/0000-0002-1558-5916
Esteves-Leuenberger, Line
Campos, Jérémy
Farina, Alex
Fiscalini, Flurin
Dereuddre-Bosquet, Nathalie https://orcid.org/0000-0001-6682-6313
Relouzat, Francis
Abdelnabi, Rana https://orcid.org/0000-0001-9771-7312
Foo, Caroline S. https://orcid.org/0000-0002-6380-4917
Neyts, Johan https://orcid.org/0000-0002-0033-7514
Leyssen, Pieter https://orcid.org/0000-0002-7537-1688
Lévy, Yves https://orcid.org/0000-0002-5549-6256
Pojer, Florence
Stahlberg, Henning https://orcid.org/0000-0002-1185-4592
LeGrand, Roger
Trono, Didier https://orcid.org/0000-0002-3383-0401
Pantaleo, Giuseppe https://orcid.org/0000-0003-3651-2721
- License Information
-
More Information
Article History
Received: 8 June 2022
Accepted: 6 July 2022
First Online: 25 July 2022
Competing interests
: C.F., G.P., P.T. and D.T. are co-inventors on a patent application that encompasses the antibodies and data described in this manuscript (EP 22153464.7 and PCT/IB2022/050731). D.T. and G.P. are among the founders of and own equity in Aerium Therapeutics, which has rights to and is pursuing the development of the antibodies described in the publication, and has Sponsored Research Agreements with the Lausanne University Hospital (CHUV) and the Ecole Polytechnique Fédérale de Lausanne (EPFL). The other authors declare no competing interests.
